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ABSTRACT 
Iron is one of the essential elements involved in many cellular processes that are necessary for life, including oxygen sensing, oxygen transport, 
electron transfer, energy metabolism, DNA synthesis etc. Although, iron is not readily available in the naturally available iron III form, 
microorganisms have evolved to produce smaller high affinity chelating small organic molecules called siderophores for its acquisition. The study of 
siderophores has opened up investigations of small-molecule inhibitors, which can hinder the biosynthesis of siderophores and thereby suppress 
the growth and virulence of bacteria in iron-limiting backgrounds. One of the most important applications of siderophores is selective drug delivery 
to defeat drug-resistant bacteria. It uses the iron transport capabilities of siderophores in carrying drugs/molecules into cells, synthetic through 
conjugates between siderophores and antimicrobial agents forming sideromycins. Some siderophore such as Desferrioxamine B have been found to 
be useful in the treatment of malaria caused by Plasmodiumfalciparum through intracellular iron depletion mechanisms. Importantly, iron overload 
diseases can be efficiently treated with siderophore based drugs as they can quench iron effectively. Moreover, siderophores such as dexrazoxane, 
desferriexochelins, isonicotinoyl hydrazine derivatives are being used in cancer therapy, as they prevent the formation of free radicals by reducing 
iron and retard the tumor growth by disturbing the iron regulation in tumor cells. In addition to bacterial siderophores, it is reported that plant-
derived polyphenols, phenolic acids,and flavonoid compounds show siderophores like activity scavenging iron which gives rise to their antioxidant 
and anticancer activity.  
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INTRODUCTION 
Iron is indispensable to all living organisms. The unique chemistry of 
iron helps it to coordinate and activate molecular oxygen; its perfect 
redox chemistry comprising of three oxidation states [Fe (II), Fe 
(III), Fe(IV)] allows it to be involved in the electron transport and 
other important metabolic processes. Although, iron is plentiful in 
the earth’s crust, its bioavailability in the aerobic environment is 
compromised due to the very low solubility of Fe(OH) 3
Siderophores exhibit a higher affinity for Fe (III) compared to Fe (II). 
By understanding that it is difficult to design ligands which are 
selective to Fe (II) over other biologically important cations like Ni 
(II), Zn (II), Cu (II) and Mn (II), one can appreciate this affinity for Fe 
(III). However, any ligand selective for Fe (III) will also be selected 
for other trivalent cations as well. One possible competitor for Fe 
(III) which is biologically important is Co (III), which, fortunately, is 
kinetically inert. Another ubiquitous trivalent metal Al (III), because 
of its smaller ionic radius (0.54 Å) compared to Fe (III) (0.65 Å), has 
a significantly less affinity for siderophores. For example, the log 
affinity constants of Al (III) and Fe (III) for desferrioxamine B are 
21.4 and 30.6, respectively [4].  
. In the face 
of this dilemma–high abundance, but low availability–living 
organisms have developed various stratagems to scavenge and 
absorb iron from the environment. One of the commonest such ploys 
is the production of low molecular weight organic compounds 
referred to as siderophores (from the Greek: iron carriers). Today, 
over 270 such compounds have been structurally characterized [1] 
and synthetic routes for their abiotic preparation have been 
elaborated [2, 3]. Some notable siderophores with high affinity are 
mycobactin, ferrichrome, arthrobactin and desferrioxamine B.  
Siderophores possess charged oxygen atoms to bind Fe (III) in an 
octahedral environment. Thus, with six ligands around the iron atom, 
there is a minimum repulsion between ligands which allows 
thermodynamically stable high-spin Fe (III) species. In siderophores, 
in addition to oxygen, sometimes N or S is used as donor atoms leading 
to a lesser affinity for Fe (III). After the Fe (III) is sequestered by the 
siderophore molecule, cellular uptake can take place either by release 
of iron through reduction at the extracellular surface or by the 
internalization of the whole siderophore-Fe (III) complex. Filamentous 
fungi and yeast (eukaryotes) owing to their membrane-standing 
ferrisiderophore reductases are capable of Fe (III) uptake via both 
pathways. However, in bacteria, the main uptake route is by 
internalization of the iron-siderophore complex [5]. 
Microbes have adapted to utilize siderophores by regulating 
enzymes and transport systems which allow concerted biosynthesis, 
secretion, iron-siderophore complex uptake, and release of iron. 
Gene regulation of siderophore deployment and iron homeostasis is 
decided at the transcriptional level by the ferric uptake repressor, 
Fur, or the diphtheria toxin regulator, DtxR[6]. Fur is the iron 
regulator in many gram-negative bacteria (enteric bacteria) while 
DtxR regulates iron in many gram-positive bacteria. Interestingly, 
the bacteria that regulate iron homeostasis by these two pathways 
also regulate manganese [5].  
Bacteria have evolved to produce siderophores with a variety of 
structural groups such as catecholate, phenolate, hydroxamate, 
carboxylate, and mixtures of the above functional groups (fig. 1).  
Ecological dynamics of siderophores 
In the environment, in places where iron bioavailability is low, 
siderophores assume an important role, especially for iron-
dependent aerobic microorganisms [7]. Many of the soil bacteria and 
fungi secrete siderophores. As a side benefit, these siderophores 
serve all microbes which are able to utilize them. Bacterial genera 
such as Bacillus, Arthrobacter and Norcardia and the fungi 
Aspergillus and Penicilliumproduce ferrioxamines (ferrichrome, 
desferrioxamine B). The mycorrhizal fungi Wilcoxinarehmii and 
Cenococcumgeophilium secrete ferricrocin (fig. 2) whose 
concentration in many forest soils can reach as high as 10 mM [1]. In 
fresh water, such as rivers and estuaries, the iron content is high and 
the mechanism of iron absorption by bacteria is presently unknown. 
On the other hand, the Fe (III) concentration of marine water is 
extremely low (1 nM to 1 mM in the upper 200 m), lower than V, Ni, 
Co etc. These levels do not allow a significant growth of 
phytoplanktons. Therefore, a sudden influx of iron would give rise to 
algal blooms which has given rise to an intriguing theory that added 
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iron would reduce atmospheric CO2
There are two types of iron binding proteins in most animals which 
offer protection against microbial attack: extracellular protection is 
given by transferrin proteins while ferritin provides intercellular 
protection. Transferrin which contains two binding sites is present 
in the serum at about 30 mM concentration. Usually, it is about 25-
40% saturated with iron which means that no sooner than iron 
appears in the serum it will be scavenged, thereby precluding 
microbial growth. Most siderophores are incapable of removing iron 
from ferritin with the exception of aerobactin [9]. In mammals, 
lactoferrin (similar in structure to transferrin) has an even higher 
binding affinity for iron compared to aerobactin (fig. 3). It is present 
in secretory fluids like sweat, tears, and milk, which helps minimize 
bacterial infection. Ferritin, present in the cytoplasm of mammalian 
cells is a much larger protein than transferrin, which can bind 
several thousand iron atoms in a non-toxic form [8]. It can control 
the intracellular iron level to 1 mM. In addition to, “iron scavenging” 
strategies, mammals elaborate an iron-siderophore binding protein 
called siderochalin. It has three positively charged residues in the 
hydrophobic pocket, which binds highly effectively with Fe (III)-
enterobactin. Thus, siderochalin, secreted by macrophages and 
hepatocytes, is a powerful bacteriostatic agent against E. coli 
scavenging enterobactin from extracellular spaces [1]. Indeed, mice 
are greatly vulnerable to E. coli infections when the siderochalin 
gene is “knocked out” [10]. 
 by increasing the 
phytoplankton population [8].  
Siderophores and pathogenicity 
 
 
Fig. 1: Structural types of siderophores 
 
There are instances whereby modifications to their structure, 
siderophores avoid being detected by siderochalin and are able to 
carry out iron scavenging activities. Pathogens have developed such 
strategies for survival in animal tissue; in spite of the wide array of 
siderophore structural motifs, microbes infect animals, only if 
normal barriers become non-functional such as through an open 
wound. During iron overload, caused by regular blood transfusions, 
transferrin becomes fully saturated and then the animal is more 
susceptible to disease.  
 
 
Fig. 2: Siderophores in ecology and pathogenicity 
Another tactic for control of iron-dependent pathogen attack is by 
rendering the siderophores ineffective. One of the earliest reports in 
this area is the antitubercular drug p-aminosalicylic acid caused 
inhibition of the siderophore mycobactin in Mycobacterium 
smegmatis [11]. Research into target-specific inhibition of 
siderophore biosynthesis is a future area owing to the accessibility 
of enzyme crystal structures which enable rational design of 
catalytic site inhibitors [12]. 
Siderophores as antibiotics 
Antibiotic resistance by bacteria continues to unfold as a major 
problem facing the health industry and requires new and efficient 
therapeutics [13]. Bacterial pathogens resist antibiotics with 
strategies such as the outer membrane permeability barrier, drug 
inactivating enzymes, target al. teration and efflux [14]. The outer 
membrane permeability barrier is particularly severe in Gram-
negative bacteria such as Pseudomonas aeruginosa, Burkholderia 
cepacia, and Streptophomonasmaltophilia which are the major 
pathogens associated with pneumonia and bacteremia in 
immunocompromised hosts, having destructive lung infections, in 
cystic fibrosis patients, and with severe nosocomial infections in 
ventilated patients [14]. Pseudomonas aeruginosa is well known for 
its ability to develop multidrug resistance after antibiotic therapy. 
One of the strategies to overcome these resistance mechanisms is by 
the “ill-use” of bacterial iron transport systems–siderophores. Since 
they are vital for virulence and persistence of bacteria on the 
infected host, they can go through the permeability barrier carrying 
a “payload” of an antibiotic. There are several natural siderophore-
antibiotic conjugates (SDCs) called sideromycins produced by 
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bacteria such as albomycin (fig. 3) by Actinomycessubtropicus[15], 
ferrimycin by Streptomyces griseoflavus[16], and salmycin by 
Streptomyces violaceus[17] where the antibiotic is covalently 
attached to the siderophore. These sideromycins which are actively 
transported into bacteria can lower the minimum inhibitory 
concentration of the antibiotic as much as 100 fold [18].  
 
 
Fig. 3: Siderophore-antibiotic conjugates 
 
Taking lessons from nature, “biomimetic” siderophoes have been 
synthesized as shuttle vectors for active transport of antibiotics. 
Furthermore, the delicate balance of iron homeostasis in all organisms 
makes this approach even more desirable. One of promising SDCs 
contains ß-lactam antibiotics as the drug. Here, since the penicillin-
binding proteins are located in the periplasm, only the outer 
membrane has to be navigated by the SDC. Importantly, the reduced 
permeation of amino-penicillin antibiotics through the outer 
membrane of bacteria can be reduced by conjugation to a siderophore. 
In addition, the active uptake of such conjugates will not be subjected 
to efflux pumps in P. aeruginosa. Preliminary studies indicate they 
possess good in vitro activity against gram-negative bacteria and 
potent in vivo activity against P. aeruginosa [19]. A large number of 
such conjugates which can effectively bind to Fe (III) which are 
hexadentate (hydroxamate) or tetradentate (biscatecholate containing 
the ß-lactam moiety have been made. The use of mixed ligand 
conjugates offer further advantages; they can be taken up by several 
pathways, therefore, leads to a less frequent of resistant bacterial 
mutants and a hydroxamate-biscatecholate-carbacephem conjugate 
was found to be 2000 fold more effective than the parent drug 
loracarbef (Lorabid) [20]. 
Antimalarial agents, iron overload therapy, and anticancer 
treatment 
Desferrioxamine B which is a linear trihydroxamate is used for in 
vitro and in vivo treatment of Plasmodium falciparum. Studies 
indicate that its mechanism of action is via intracellular iron 
depletion of the parasite [21]. Desferrioxamine B conjugated with 
nalidixic acid displayed even more potent activity against multidrug-
resistant P. falciparum where iron-catalyzed oxidative DNA damage 
occurred [22].  
Besides infection control, desferrioxamine B conjugates such as 
deferiprone (Ferriprox), deferasirox (Exjade) and deferitrin (fig. 4) 
are used in iron overload therapy [23]. Although iron is a vital 
nutrient in cell proliferation and growth, it can also participate in 
redox cycling and the formation of free radicals. Thus, iron can cause 
both tumor initiation and tumor growth. It has been shown that iron 
is involved in the tumor microenvironment and in metastasis. 
Methods of iron acquisition, efflux, storage and regulation are all 
disturbed in cancer, implying that reprogramming of iron 
metabolism is critical for tumor cell survival [24]. Desferrioxamine B 
and mycobacterial desferriexochelins in addition to synthetic iron 
chelators such as dexrazoxane and isonicotinoyl hydrazine 
derivatives are used in cancer therapy [25].  
 
 
Fig. 4: Iron chelators in cancer therapy 
 
Iron chelators of plant origin 
Foods having plant polyphenols and flavonoid compounds may have 
advantages not only as powerful antioxidants, but also as iron 
chelators[26, 27]. Iron chelation by polyphenols can completely 
inhibit free radical generation, showing that chelation may be 
important to their antioxidant activity. These data validate that 
quercetin (fig. 5) and other phenolic compounds can successfully 
control iron biochemistry under physiological conditions, thus 
offering insight into the mechanism of action of bioactive phenolics. 
In addition,curcumin isolated from Picrorhizakurroa[28], kolaviron 
from Garcinia kola [29], baicalein and its glycoside baicalein, the 
major bioactive compounds found in the Chinese 
herb Scutellariabaicalensis[30], tetramethylpyrazine and ferulic acid, 
from the Chinese herbal medicine Ligusticumwallichi[31] and p-
courmaric acid found in many sources including Costusspeciosus 
 
[32] 
have been implicated in iron chelation resulting in anticancer 
activity [33]. Recently, Coriander sativa in extracts, containing high 
phenol and flavonoid content, the antioxidant activity correlated 
with the iron chelating potential [34]. Siderophores have also the 
ability to activate plant immunity [35, 36]. In Arabidopsis plants, the 
siderophonedeferrioxamine was able to provide protection against 
the pathogenic bacterium Pseudomonas syringaepv tomato DC3000. 
 
Fig. 5: Iron chelators of plant origin 
Karunaratne et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 8-12 
 
11 
In addition to p-coumaric acid, caffeic and ferulic acids, and trans-
cinnamic (fig. 5) is reported to possess the protective activity of cells 
from free radical generated oxidative stress-induced DNA damage. 
This protection was grounded in the capacity of these compounds to 
access the intracellular space and chelate "labile" iron. Thus, many 
plant-derived lipophilic iron chelating compounds, may shield cells 
from oxidative stress thus contributing to the preservation of human 
health [37]. 
Interestingly, lichens which are slow growing non-flowering plants 
produce a large variety of phenolic lichen substances [38, 39]. These 
compounds, mostly simple aromatics, depsides and depsidones 
possesses potent antioxidant activity and metal ion chelating ability 
[40-43]. The ecological role of these lichen substances is considered 
to be in providing protection to their thalli open to the environment. 
Studies have confirmed that their antioxidant activity may be related 
to their iron chelating ability. It is interesting to note that both 
higher plants and lower plants engage in iron sequestration through 
phenolics of different biosynthetic origin.  
 
 
Fig. 6: Iron chelators of lichen origin 
 
CONCLUSION 
The foregoing discussion highlights the importance of Iron (III) 
chelating small molecule natural products. Secreted by many aerobic 
soil bacteria and fungi, they help the microbial ecology in the soil. In 
addition, they are implicated in the pathogenesis of animals and 
humans. Biomimetic synthetic analogs of siderophores have been 
used as novel antibiotics in cases of multidrug resistance. The plant-
derived phenolic compounds, both from higher plants and lichens, 
which are capable of chelating to Iron (III) are important in 
combating oxidative stress which is important not only in allowing 
them to survive in their natural environments, but also in 
prevention of cancer and improving human health. 
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